# US 10,766,929 B2 · De novo designed hemagglutinin binding proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,766,929 B2
- Document ID: US10766929B2
- Status: Granted
- Kind: B2
- Application number: 16/483,865
- Filed: 2018-03-15
- Published: 2020-01-16
- Granted: 2020-09-08
- Earliest claimed: 2017-03-15
- Assignees: University of Washington
- Applicants: University of Washington
- Inventors: David Baker; Aaron Arthur Chevalier; Gabriel Jacob Rocklin; Christopher David Bahl; Lance Joseph Stewart; Daniel Adriano Silva Manzano; Deborah L. Fuller; Merika Treants Koday; Jason Gilmore
- Web page: https://patentgrep.com/patent/US10766929B2

## CPC

- C07K 14/001: {by chemical synthesis}
- A61P 31/16: for influenza or rhinoviruses
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- G01N 33/56983: {Viruses}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2333/11: Orthomyxoviridae, e.g. influenza virus
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Polypeptides that bind to viral hemagglotinin are disclosed and methods for their use in treating or limiting influenza infection, and diagnosing influenza infection.

## Claims

### Claim 1

An isolated polypeptide, comprising an amino acid sequence having the amino acid sequence of any one of SEQ ID NOS: 1, 351-352, 378-379, 381-382, and 455-462.

### Claim 2 (depends on 1)

The isolated polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:379 or 459-462.

### Claim 3 (depends on 1)

An isolated nucleic acid encoding the polypeptide of claim 1.

### Claim 4 (depends on 3)

A recombinant expression vector comprising the nucleic acid of claim 3, operatively linked to a suitable control sequence.

### Claim 5 (depends on 4)

A recombinant host cell comprising the recombinant expression vector of claim 4.

### Claim 6 (depends on 1)

An antibody that selectively binds to the polypeptide of claim 1.

### Claim 7 (depends on 1)

A pharmaceutical composition, comprising one or more polypeptides according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

A method for limiting and/or treating an influenza infection, comprising administering to a subject in need thereof aft therapeutically effective amount of one or more polypeptides of claim 1, salts thereof, conjugates thereof, or pharmaceutical compositions thereof, to treat and/or limit the influenza infection.

### Claim 9 (depends on 8)

The method of claim 8, wherein an effective amount of one or more polypeptides are administered mucosally, intranasally, or orally.

### Claim 10 (depends on 7)

A method for diagnosing an influenza infection, or monitoring progression of an influenza infection, comprising
(a) contacting a biological sample from a subject suspected of having an influenza infection with a diagnostically effective amount of one or more polypeptides of claim 7, under conditions suitable for binding of the polypeptide to a viral hemagglutinin protein present in the sample; and
(b) detecting polypeptide-viral hemagglutinin binding complexes,
where the presence of such binding complexes indicates that the subject has an influenza infection, or provides a measure progression of an influenza infection.

### Claim 11 (depends on 1)

The isolated polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

### Claim 12 (depends on 1)

The isolated polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:379.

### Claim 13 (depends on 1)

The isolated polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:459.

### Claim 14 (depends on 1)

The isolated polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:460.

### Claim 15 (depends on 1)

The isolated polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:461.

### Claim 16 (depends on 1)

The isolated polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:462.

### Claim 17 (depends on 2)

An isolated nucleic acid encoding the polypeptide of claim 2.

### Claim 18 (depends on 17)

A recombinant expression vector comprising the nucleic acid of claim 17, operatively linked to a suitable control sequence.

### Claim 19 (depends on 18)

A recombinant host cell comprising the recombinant expression vector of claim 18.